| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | Phase 3 | UroGen Pharma Ltd. | Arkansas City |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | Bentonville |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | Bentonville |
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. | Phase 2 | LB Pharmaceuticals Inc. | Bentonville |
| A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder | Phase 3 | Janssen Research & Development, LLC | Bryant |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | Phase 2 | AbbVie | Bryant |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | Phase 4 | Neurocrine Biosciences | Bryant |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | Phase 2/3 | Pfizer | Bryant |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | Bryant |
| NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | Bryant |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | Bryant |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | Conway |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | Hoffmann-La Roche | Conway |
| Prenatal Exercise and Glucose Regulation | N/A | University of Central Arkansas | Conway |
| Delivering HOPE (Helping Women Optimize Prenatal Equity) | N/A | University of Arkansas | Corning |
| A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension | — | Canary Medical | Fayetteville |
| A Study of DS-3939a in Participants With Solid Tumors | Phase 1/2 | Daiichi Sankyo | Fayetteville |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | Fayetteville |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | Fayetteville |
| A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC) | Phase 3 | Pfizer | Fayetteville |
| A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | Phase 3 | Pfizer | Fayetteville |
| ALTO-100 in Bipolar Disorder With Depression (BD-D) | Phase 2 | Alto Neuroscience | Fayetteville |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer | Phase 3 | SWOG Cancer Research Network | Fayetteville |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Phase 3 | Novartis Pharmaceuticals | Fayetteville |
| Appetite Response to Meals With Different Protein Sources in Women With PCOS | N/A | University of Arkansas, Fayetteville | Fayetteville |
| Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence | Phase 2 | University of Arkansas | Fayetteville |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | Fayetteville |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | Fayetteville |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | Fayetteville |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | Fayetteville |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | Fayetteville |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | Fayetteville |
| Persona Revision Knee System Outcomes | — | Zimmer Biomet | Fayetteville |
| Physical Activity and Community EmPOWERment Project | N/A | University of North Carolina, Chapel Hill | Fayetteville |
| Protein and Polycystic Ovary Syndrome (PCOS) | N/A | University of Arkansas, Fayetteville | Fayetteville |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy | Phase 2 | National Cancer Institute (NCI) | Fayetteville |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | Fayetteville |
| Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | Fayetteville |
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET | Phase 3 | Novartis Pharmaceuticals | Fayetteville |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | Fayetteville |
| Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | Phase 3 | Pfizer | Fayetteville |
| Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | Phase 1/2 | Pfizer | Fayetteville |
| Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Phase 1/2 | Pfizer | Fayetteville |
| Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Pfizer | Fayetteville |
| Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | Phase 2/3 | Pfizer | Fayetteville |
| Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | Phase 1/2 | Pfizer | Fayetteville |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | SWOG Cancer Research Network | Fayetteville |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | Fayetteville |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body | Phase 3 | SWOG Cancer Research Network | Fayetteville |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | Fayetteville |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer | Phase 3 | National Cancer Institute (NCI) | Fayetteville |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Phase 2 | National Cancer Institute (NCI) | Fayetteville |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | Fayetteville |
| This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. | Phase 3 | Pfizer | Fayetteville |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Phase 2 | SWOG Cancer Research Network | Fort Smith |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | Fort Smith |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | Fort Smith |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | Fort Smith |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | Fort Smith |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | Fort Smith |
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer | — | National Cancer Institute LAO | Fort Smith |
| Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects | — | Alliance for Clinical Trials in Oncology | Fort Smith |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | Fort Smith |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Phase 3 | SWOG Cancer Research Network | Fort Smith |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | Fort Smith |
| Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) | N/A | ECOG-ACRIN Cancer Research Group | Fort Smith |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | Fort Smith |
| Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | Phase 3 | SWOG Cancer Research Network | Fort Smith |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | Fort Smith |
| Family Communications After Genetic Testing | N/A | Alliance for Clinical Trials in Oncology | Fort Smith |
| Fasted vs. Fed State Exercise | Phase 2 | Arkansas Colleges of Health Education | Fort Smith |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | Fort Smith |
| GEMINI-NSCLC: NSCLC Biomarker Study | — | Tempus AI | Fort Smith |
| Galleri® in the Medicare Population. | N/A | GRAIL, Inc. | Fort Smith |
| Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors | — | SWOG Cancer Research Network | Fort Smith |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Phase 2 | National Cancer Institute (NCI) | Fort Smith |
| Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia | Phase 3 | Alliance for Clinical Trials in Oncology | Fort Smith |
| LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia | — | University of Rochester | Fort Smith |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | Fort Smith |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | Fort Smith |
| Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05) | — | Elephas | Fort Smith |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | Fort Smith |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | Fort Smith |
| Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program | Phase 3 | Alliance for Clinical Trials in Oncology | Fort Smith |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | Fort Smith |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | Fort Smith |
| Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | Phase 3 | ECOG-ACRIN Cancer Research Group | Fort Smith |
| Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | N/A | Alliance for Clinical Trials in Oncology | Fort Smith |
| Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study | — | Wake Forest University Health Sciences | Fort Smith |
| Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays | — | Tempus AI | Fort Smith |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | Fort Smith |
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | Phase 2 | National Cancer Institute (NCI) | Fort Smith |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | Fort Smith |
| Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer | N/A | Alliance for Clinical Trials in Oncology | Fort Smith |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | Fort Smith |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | Fort Smith |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | Fort Smith |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | Fort Smith |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | Fort Smith |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | Fort Smith |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | Fort Smith |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | Fort Smith |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | Fort Smith |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | Hot Springs |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | Hot Springs |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | Hot Springs |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | Hot Springs |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | Hot Springs |
| A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | Phase 3 | Bristol-Myers Squibb | Hot Springs |
| A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer | Phase 1 | TerSera Therapeutics LLC | Hot Springs |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | Hot Springs |
| An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC | Phase 3 | AstraZeneca | Hot Springs |
| An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. | Phase 4 | AstraZeneca | Hot Springs |
| BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease | Phase 3 | BeOne Medicines | Hot Springs |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | Hot Springs |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | Hot Springs |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | Hot Springs |
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | Hot Springs |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | Hot Springs |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | Phase 2/3 | Eikon Therapeutics | Hot Springs |
| Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05) | Phase 3 | AstraZeneca | Hot Springs |
| Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Phase 2/3 | Panbela Therapeutics, Inc. | Hot Springs |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) | Phase 3 | Genmab | Hot Springs |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | Phase 3 | Gilead Sciences | Hot Springs |
| A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer | Phase 3 | Takeda | Jonesboro |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | Jonesboro |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | Jonesboro |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | Phase 3 | GlaxoSmithKline | Jonesboro |
| A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | Phase 3 | BeOne Medicines | Jonesboro |
| A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment | Phase 2 | Alliance for Clinical Trials in Oncology | Jonesboro |
| A Study of VARIPULSE Catheter in Participants With Persistent Atrial Fibrillation Undergoing Pulmonary Vein and Superior Vena Cava Isolation | N/A | Biosense Webster, Inc. | Jonesboro |
| A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation | N/A | Biosense Webster, Inc. | Jonesboro |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Phase 2 | AbbVie | Jonesboro |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | Phase 3 | Janssen Research & Development, LLC | Jonesboro |
| AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions | N/A | Boston Scientific Corporation | Jonesboro |
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | Phase 3 | SWOG Cancer Research Network | Jonesboro |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | Jonesboro |
| Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study | N/A | Vektor Medical | Jonesboro |
| BoxX-NoAF Clinical Trial | N/A | AtriCure, Inc. | Jonesboro |
| Caris Biorepository Research Protocol | — | Caris Science, Inc. | Jonesboro |
| Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation | N/A | Arga Medtech SA | Jonesboro |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | Jonesboro |
| Detection of Atrial Fibrillation Using PPG From Smartphone Cameras | — | Happitech BV | Jonesboro |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | Jonesboro |
| Elite AF IDE Trial (Elite AF) | N/A | Boston Scientific Corporation | Jonesboro |
| Evaluation of the FARAFLEX Mapping and Pulsed Field Ablation System in Subjects With Atrial Fibrillation | N/A | Boston Scientific Corporation | Jonesboro |
| Globe Registry: Globe® Pulsed Field System Registry Study for Treating Patients With Symptomatic Atrial Fibrillation | — | Kardium Inc. | Jonesboro |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | Phase 3 | National Cancer Institute (NCI) | Jonesboro |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | Jonesboro |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | Jonesboro |
| Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System | — | Kansas City Heart Rhythm Research Foundation | Jonesboro |
| Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study | N/A | AtaCor Medical, Inc. | Jonesboro |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | Jonesboro |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | Jonesboro |
| Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias | — | Heart Rhythm Clinical and Research Solutions, LLC | Jonesboro |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | Jonesboro |
| Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF | N/A | Massachusetts General Hospital | Jonesboro |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | Jonesboro |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | Jonesboro |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | Jonesboro |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | Jonesboro |
| Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | Phase 3 | National Cancer Institute (NCI) | Jonesboro |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | Jonesboro |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | Jonesboro |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | Phase 2 | NRG Oncology | Jonesboro |
| The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials | N/A | Eastern Cooperative Oncology Group | Jonesboro |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | Jonesboro |
| The WiSE®-UP Study (The WiSE System Utilization & Performance Study) | — | EBR Systems, Inc. | Jonesboro |
| Tracking Results of Ablations to Combat AF Registry Generation 2 | — | AtriCure, Inc. | Jonesboro |
| ViewFlex X ICE First-in-Human Study | — | Abbott Medical Devices | Jonesboro |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | Little Rock |
| A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy | Phase 1 | University of Arkansas | Little Rock |
| A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Phase 1/2 | Eikon Therapeutics | Little Rock |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | Little Rock |
| A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM | Phase 3 | AstraZeneca | Little Rock |
| A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab | — | Arkansas Children's Hospital Research Institute | Little Rock |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | Little Rock |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | Context Therapeutics Inc. | Little Rock |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Phase 1/2 | Nkarta, Inc. | Little Rock |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | Little Rock |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | Little Rock |
| A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend) | Phase 3 | Definium Therapeutics US, Inc. | Little Rock |
| A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin | Phase 3 | AstraZeneca | Little Rock |
| A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus | Phase 3 | AstraZeneca | Little Rock |
| A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | Phase 3 | GlaxoSmithKline | Little Rock |
| A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 3 | GlaxoSmithKline | Little Rock |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | Little Rock |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Phase 3 | Novo Nordisk A/S | Little Rock |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Phase 3 | Novo Nordisk A/S | Little Rock |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) | Phase 3 | Children's Oncology Group | Little Rock |
| A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | Little Rock |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | Little Rock |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | Little Rock |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | Little Rock |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | Little Rock |
| A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2) | Phase 3 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | Little Rock |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | Little Rock |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 3 | Janssen Research & Development, LLC | Little Rock |
| A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease | Phase 4 | Impax Laboratories, LLC | Little Rock |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | Little Rock |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | Little Rock |
| A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF) | Phase 2 | Edgewise Therapeutics, Inc. | Little Rock |
| A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma | Phase 3 | GlaxoSmithKline | Little Rock |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | Little Rock |
| A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Phase 1 | Whitehawk Therapeutics, Inc. | Little Rock |
| A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes | Phase 3 | Ascletis Pharma (China) Co., Limited | Little Rock |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Janssen Research & Development, LLC | Little Rock |
| A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer | Phase 1/2 | SURGE Therapeutics | Little Rock |
| A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Syncromune, Inc. | Little Rock |
| A Study of Sovilnesib in Subjects With Ovarian Cancer | Phase 1 | Volastra Therapeutics, Inc. | Little Rock |
| A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Janssen Research & Development, LLC | Little Rock |
| A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer | Phase 4 | Coherus Oncology, Inc. | Little Rock |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | Little Rock |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | Little Rock |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | Little Rock |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | Little Rock |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Eccogene | Little Rock |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | Little Rock |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AbbVie | Little Rock |
| A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab | Phase 3 | AbbVie | Little Rock |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Phase 2 | AbbVie | Little Rock |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Phase 3 | Merck Sharp & Dohme LLC | Little Rock |
| A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States | — | Janssen Research & Development, LLC | Little Rock |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | Little Rock |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | Little Rock |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | Little Rock |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | Phase 3 | Celgene | Little Rock |
| A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight | Phase 3 | AstraZeneca | Little Rock |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | Little Rock |
| A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | Little Rock |
| A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations | Phase 2 | Appello Pharmaceuticals, Inc. | Little Rock |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | Hoffmann-La Roche | Little Rock |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | Little Rock |
| A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder | Phase 2 | Astellas Pharma Global Development, Inc. | Little Rock |
| A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | — | AstraZeneca | Little Rock |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | Little Rock |
| A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 3 | GlaxoSmithKline | Little Rock |
| A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) | Phase 2 | Protalix | Little Rock |
| A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase 3 | BlueRock Therapeutics | Little Rock |
| A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma | Phase 3 | AstraZeneca | Little Rock |
| A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar | Phase 3 | Boehringer Ingelheim | Little Rock |
| A Trial of Inebilizumab in Participants With Autoimmune Hepatitis | Phase 3 | Amgen | Little Rock |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | Little Rock |
| AI Algorithm-Informed Biopsy for Prostate Cancer Detection With Indeterminate and Low-Risk Prostate MRI Lesions | N/A | University of Arkansas | Little Rock |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Phase 2 | Cytokinetics | Little Rock |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | Phase 3 | AstraZeneca | Little Rock |
| Abbott Vascular Medical Device Registry | — | Abbott Medical Devices | Little Rock |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | Little Rock |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | Little Rock |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | Little Rock |
| Beat Childhood Cancer Specimen Banking and Data Registry | — | Giselle Sholler | Little Rock |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | Phase 2 | Jason Sperry | Little Rock |
| COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | N/A | Edwards Lifesciences | Little Rock |
| CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA) | N/A | VA Office of Research and Development | Little Rock |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | Little Rock |
| Clinical Evaluation of BCDx for Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer | — | Early is Good Inc. | Little Rock |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | Phase 2 | Carl Allen | Little Rock |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | Little Rock |
| Comparing Telephone Symptom Monitoring Interventions for Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment | N/A | NRG Oncology | Little Rock |
| Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers | — | ECOG-ACRIN Cancer Research Group | Little Rock |
| DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy | Phase 3 | Boehringer Ingelheim | Little Rock |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | Little Rock |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | Phase 2 | Giselle Sholler | Little Rock |
| Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix | N/A | Varian, a Siemens Healthineers Company | Little Rock |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | Little Rock |
| Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer | — | Massachusetts General Hospital | Little Rock |
| Digoxin Medulloblastoma Study | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | Little Rock |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | Little Rock |
| Effectiveness, Implementation, and Cost of Cognitive Processing Therapy in Prisons | N/A | University of Arkansas | Little Rock |
| Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing After Total Knee Arthroplasty (TKA) | N/A | University of Arkansas | Little Rock |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | Little Rock |
| Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults | N/A | University of Arkansas | Little Rock |
| Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus | Phase 2 | Sun Pharmaceutical Industries Limited | Little Rock |
| Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer | Phase 3 | Protara Therapeutics | Little Rock |
| Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 2 | Tyra Biosciences, Inc | Little Rock |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | Phase 1/2 | Milton S. Hershey Medical Center | Little Rock |
| Encore PFO Closure Device - The PerFOrm Trial | N/A | Encore Medical Inc. | Little Rock |
| Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) | Phase 3 | Astellas Pharma Global Development, Inc. | Little Rock |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | Little Rock |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 | Vanda Pharmaceuticals | Little Rock |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | Little Rock |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | Little Rock |
| Functional Assessment in Liver Transplantation | — | University of California, San Francisco | Little Rock |
| High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders | Phase 1 | University of Arkansas | Little Rock |
| High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | Little Rock |
| Impact of the Enhanced Recovery After Surgery System for Colorectal Surgery | — | University of Arkansas | Little Rock |
| In Vivo Real-time Detection of Circulating Melanoma Cells | — | University of Arkansas | Little Rock |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | Little Rock |
| Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer | Phase 1/2 | University of Arkansas | Little Rock |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | Little Rock |
| Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | N/A | BrioHealth Solutions, Inc. | Little Rock |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | Little Rock |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | Little Rock |
| Limited-duration Teclistamab | Phase 2 | Abramson Cancer Center at Penn Medicine | Little Rock |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | Little Rock |
| Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) | Phase 2 | University of Arkansas | Little Rock |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | Little Rock |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | Little Rock |
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Phase 3 | Intra-Cellular Therapies, Inc. | Little Rock |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | Little Rock |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | Phase 2 | Giselle Sholler | Little Rock |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | Phase 2 | AstraZeneca | Little Rock |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | Little Rock |
| Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC | Phase 2/3 | Urovant Sciences GmbH | Little Rock |
| PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | N/A | Kardion Inc | Little Rock |
| PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer | Phase 2 | Precigen, Inc | Little Rock |
| Pan-tumor MRD Study | — | Paradigm Health | Little Rock |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Phase 2 | Giselle Sholler | Little Rock |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | Phase 3 | Merck Sharp & Dohme LLC | Little Rock |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | Little Rock |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | Little Rock |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | Little Rock |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | Little Rock |
| Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Phase 3 | Clarity Pharmaceuticals Ltd | Little Rock |
| Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy | N/A | Proton Collaborative Group | Little Rock |
| Prevail Global Study | N/A | Medtronic Vascular | Little Rock |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | Little Rock |
| Product Surveillance Registry | — | Medtronic | Little Rock |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | Little Rock |
| Prospective Global Registry for the Study of Chronic Total Occlusion Intervention | — | Minneapolis Heart Institute Foundation | Little Rock |
| Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | Phase 2 | Proton Collaborative Group | Little Rock |
| Quality of End-of-Life Care for Children With Cancer | — | Children's Oncology Group | Little Rock |
| RE104 Safety and Efficacy Study in Generalized Anxiety Disorder | Phase 2 | Reunion Neuroscience Inc | Little Rock |
| Registry Study for Radiation Therapy Outcomes | — | Proton Collaborative Group | Little Rock |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | Little Rock |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | Little Rock |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Phase 2 | Protara Therapeutics | Little Rock |
| Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients | Phase 2 | University of Arkansas | Little Rock |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | Little Rock |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Phase 3 | Regeneron Pharmaceuticals | Little Rock |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Phase 3 | Regeneron Pharmaceuticals | Little Rock |
| Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | Phase 1 | Whitehawk Therapeutics, Inc. | Little Rock |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Little Rock |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | Little Rock |
| Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | Phase 1/2 | Laminar Pharmaceuticals | Little Rock |
| Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy | Phase 1 | Norman J. Lacayo | Little Rock |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | Phase 3 | AstraZeneca | Little Rock |
| Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease | Phase 2 | Regeneron Pharmaceuticals | Little Rock |
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | Little Rock |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | Little Rock |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Phase 1/2 | Tanja Andrea Gruber | Little Rock |
| Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | Phase 3 | Alliance for Clinical Trials in Oncology | Little Rock |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | Phase 3 | NRG Oncology | Little Rock |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | Little Rock |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | Little Rock |
| Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care Teams | N/A | SWOG Cancer Research Network | Little Rock |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | Little Rock |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | Little Rock |
| Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | Phase 2 | Alliance for Clinical Trials in Oncology | Little Rock |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| The Ailliance Post-Market Clinical Study | N/A | Medtronic Spinal and Biologics | Little Rock |
| The HEARTFELT Study | N/A | Heartfelt Technologies | Little Rock |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | Little Rock |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | Little Rock |
| Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma | Phase 2 | Giselle Sholler | Little Rock |
| Transformative Research in Diabetic Nephropathy | — | University of Pennsylvania | Little Rock |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | Phase 2 | Aadi Bioscience, Inc. | Little Rock |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | Little Rock |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | Little Rock |
| Using Virtual Reality Technology to Improve Patient Experience and Quality of Care During Brachytherapy | N/A | University of Arkansas | Little Rock |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | Little Rock |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | Little Rock |
| Veteran-Centered Care for Advanced Liver Disease (Vet-CALD) | N/A | VA Office of Research and Development | Little Rock |
| Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals | N/A | University of Arkansas | Little Rock |
| Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia | Phase 3 | Children's Oncology Group | Little Rock |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | North Little Rock |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | North Little Rock |
| A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | Rogers |
| ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours | Phase 1 | Adcendo ApS | Rogers |
| BostonGene and Exigent Genomic INsight Study | — | BostonGene | Rogers |
| Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder | Phase 2 | Supernus Pharmaceuticals, Inc. | Rogers |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | Rogers |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 | UCB Biopharma SRL | Searcy |
| A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis | Phase 2 | Janssen Research & Development, LLC | Searcy |
| A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | Phase 2 | Merck Sharp & Dohme LLC | Springdale |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | Springdale |
| A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer | Phase 1 | Stemline Therapeutics, Inc. | Springdale |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | Springdale |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | Phase 3 | AstraZeneca | Springdale |
| A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | Springdale |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Phase 3 | Mirati Therapeutics Inc. | Springdale |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | Springdale |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | Springdale |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | Springdale |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | Phase 3 | Merck Sharp & Dohme LLC | Springdale |
| A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer | Phase 3 | AbbVie | Springdale |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | AbbVie | Springdale |
| A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | Springdale |
| A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | Phase 2/3 | Bristol-Myers Squibb | Springdale |
| A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma | Phase 1 | Shanghai Henlius Biotech | Springdale |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | Springdale |
| BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) | Phase 3 | SystImmune Inc. | Springdale |
| Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In | Phase 3 | ImmunityBio, Inc. | Springdale |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Phase 2 | Merck Sharp & Dohme LLC | Springdale |
| Family Model DSME in FBOs in the RMI | N/A | University of Arkansas | Springdale |
| First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors | Phase 1 | Adcendo ApS | Springdale |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | Springdale |
| ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | Phase 3 | BioNTech SE | Springdale |
| Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors | Phase 1/2 | OncoC4, Inc. | Springdale |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | Springdale |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | Springdale |
| Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | Phase 2 | Black Diamond Therapeutics, Inc. | Springdale |